The Regulatory Stack That Determines Whether Your Ads Survive
We have built peptide ad campaigns under every regulatory framework that applies to compounded medications and supplements. The regulatory stack is not optional reading. It is the exact checklist that Meta, Google, and the FTC use when they evaluate your ads. If you understand it, you can design campaigns that pass review every time. If you ignore it, you are gambling.
Most peptide advertisers treat compliance as something you do after the ban. We treat it as the design constraint that shapes the entire campaign before a single ad goes live. The approach is slower at the start but faster over the long term because you never lose a week to an account suspension.
FDA 503A and 503B Compounding Framework
FDA 503A governs traditional compounding pharmacies that prepare customized medications for individual patients based on a valid prescription. Pharmacies operating under 503A may compound drugs that are not commercially available, in limited quantities, for identified individual patients. Advertising under 503A requires that you promote a service, not a product.
This is where most advertisers go wrong. They write ad copy that says 'Buy semaglutide' or 'Order tirzepatide online.' That is product advertising, and it triggers every automated enforcement system on both platforms. The correct approach is 'Compounded GLP-1 medications available through licensed pharmacy consultation.' The difference is the difference between an approved ad and a banned ad.
FDA 503B covers outsourcing facilities that compound sterile products in bulk for healthcare facilities. 503B facilities face additional requirements: they must comply with Current Good Manufacturing Practices, submit adverse event reports, and label products with specific statements including 'This is a compounded drug.' Advertising for 503B facilities must emphasize the facility's registration status and quality controls, not patient outcomes.
Neither 503A nor 503B allows you to claim your compounded drugs are FDA-approved. They are prepared under FDA regulations, not individually approved. This distinction must appear in your advertising and on every landing page you run.
Where DSHEA 1994 Supplement Claims Cross the Line
The Dietary Supplement Health and Education Act of 1994 sets strict limits on supplement advertising. Under DSHEA Section 6, you cannot claim a supplement treats, cures, mitigates, or prevents any disease. This includes implied claims. If your ad copy says 'supports healthy weight management' next to an image of someone stepping on a scale, the FTC considers that an implied disease claim.
Structure-function claims are permitted under DSHEA but require the standard disclaimer. Examples of acceptable structure-function claims include 'supports immune function' and 'promotes digestive health.' Examples of prohibited disease claims include 'reduces inflammation,' 'lowers blood sugar,' and 'treats chronic pain.' The line is whether the claim describes what the supplement does to the structure or function of the body versus what disease it treats.
The FTC enforces DSHEA advertising provisions and requires that all claims be substantiated by competent and reliable scientific evidence. For peptide supplements, this means maintaining documentation of the studies supporting any structure-function claim you make. If the FTC requests substantiation and you cannot produce it, the penalty is not just a ban. It is a federal enforcement action.
Platform-Specific Policy Overlays
Meta's advertising policies layer additional restrictions on top of federal regulations. Meta prohibits ads that promote the sale or use of illegal, prescription, or recreational drugs. Even if your compounded peptide is legal under FDA 503A, Meta's policy treats it as a restricted substance requiring verified business documentation through the BAV process.
Google requires healthcare advertisers to complete its healthcare and medicines certification. This process verifies your pharmacy license, your NPI number, and your compliance with applicable laws. Without certification, no peptide ad runs on Google regardless of how compliant the ad copy is.
Both platforms reserve the right to apply stricter standards than federal regulations. A campaign that is fully compliant with FDA 503A and DSHEA can still be rejected if it triggers Meta's internal risk models. This is why we treat platform policy as a separate compliance layer, not a subset of federal regulations.
The Compliance Overhaul That Saved a Peptide Company
A client running both compounded peptides and peptide-based supplements had their ads rejected across Meta, Google, and TikTok over a six-week period. They were using the same ad creative for both product categories, making health claims across the board, and linking to a landing page with no regulatory disclaimers whatsoever.
We split their product line into three compliance tracks. Track one: 503A compounded drugs advertised as consultation services with pharmacy license verification. Track two: 503B compounded drugs advertised with facility registration numbers and sterility documentation. Track three: DSHEA supplements advertised with structure-function claims and the standard FDA disclaimer on every page. We completed BAV verification and Google healthcare certification simultaneously.
The result: 95% ad approval rate across all three tracks, zero account suspensions over 14 months, and the client now has a compliance framework they can apply to every new product they launch. The upfront time investment was about three weeks. The return was not having to rebuild ad accounts from scratch ever again.
Related guides
Why Are Peptide Ads Getting Banned
Compounding Pharmacy Ads Banned
Ready to run these ads? Book a call → calendly.com/custodio-2/30min